Oliver G Ottmann1, Dieter Hoelzer. Show Affiliations » 1. Medizinische Klinik III, Department of Hematology and Oncology, Johann Wolfgang Goethe-Universität, Frankfurt, Germany. ottman@em.uni-frankfurt.de
Abstract
Entities: Chemical Disease
Mesh: See more » Antineoplastic Agents/administration & dosageAntineoplastic Agents/standardsAntineoplastic Agents/therapeutic useBenzamidesDrug ResistanceFusion Proteins, bcr-abl/drug effectsFusion Proteins, bcr-abl/geneticsHumansImatinib MesylatePiperazines/administration & dosagePiperazines/standardsPiperazines/therapeutic usePrecursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapyProtein-Tyrosine Kinases/antagonists & inhibitorsPyrimidines/administration & dosagePyrimidines/standardsPyrimidines/therapeutic useTreatment Outcome
Substances: See more » Antineoplastic AgentsBenzamidesPiperazinesPyrimidinesImatinib MesylateProtein-Tyrosine KinasesFusion Proteins, bcr-abl
Year: 2002 PMID: 11960387 DOI: 10.1038/sj.thj.6200151
Source DB: PubMed Journal: Hematol J ISSN: 1466-4860